Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive ...

The 466,000 sq ft centre will serve as a hub to join Novartis' current R&D sites in Cambridge, Massachusetts, and Basel, ...

The new year brought a slew of new faces in the pharma and biotech world, especially in the top jobs, with a number of CEO ...

Eli Lilly has deepened its ties with Chinese biopharma company Innovent Biologics, signing a seventh R&D collaboration that includes a $350 million upfront payment.

Eli Lilly has signed its second pipeline-building deal in two days, reaching an agreement to buy in vivo CAR-T developer Orna Therapeutics for up to $2.4 billion.

Wegovy is the first GLP-1 to be available in the US for weight loss in an oral formulation, and Novo Nordisk has already reported strong take-up, with 170,000 people taking the drug as of last week, ...

The uptick in Leqembi (lecanemab) sales comes a few months after the FDA approved a once-weekly subcutaneous injection ...

The loss of market exclusivity for a trio of big-selling drugs in the last quarter of 2025 dragged down Novartis sales, but ...

European biotechs continue to face a demanding investment climate characterised by investor caution. As a result, many are ...

Sam Possemiers, CEO of MRM Health, believes that the space is finally coming into maturity. At his own company, that’s in the ...

A wireless sensor the size of a paperclip, Abbott's CardioMEMS HF, can be used routinely by the NHS to monitor patients with ...

Incubated by Flagship Pioneering, Generate applies AI to teasing out the three-dimensional structure of human proteins, ...